Cardiovascular Disease in Autoimmune Rheumatic Disorders: From Pathophysiology to Clinical Management

Cardiovascular disease in autoimmune rheumatic disorders encompasses accelerated atherosclerosis, inflammatory myocardial and pericardial injury, valvular abnormalities, pulmonary vascular disease, and thrombosis. These complications overlap clinically but arise through different combinations of conventional risk factors, immune activation, tissue damage, and treatment exposure. Rheumatoid arthritis and systemic lupus erythematosus provide strong epidemiological evidence of premature vascular events, whereas systemic sclerosis highlights the importance of pulmonary arterial hypertension and myocardial involvement. Antiphospholipid syndrome requires particular attention to thrombotic mechanisms rather than an exclusively atherosclerotic interpretation of vascular disease. Experimental studies implicate endothelial injury, impaired vascular repair, altered lipoprotein function, and inflammatory arterial stiffening, but laboratory findings and surrogate improvements do not establish reductions in clinical events. Associations between lower rheumatic disease activity and fewer cardiovascular outcomes support coordinated disease control and prevention while remaining vulnerable to treatment selection and residual confounding. Clinical assessment should therefore distinguish the cardiovascular phenotype before selecting investigations or treatment. Pulmonary hypertension screening has an established disease-specific role in systemic sclerosis, whereas broad imaging of asymptomatic patients across all rheumatic diagnoses lacks equivalent justification. Prevention includes smoking cessation, physical activity adapted to functional capacity, blood pressure management, and lipid treatment guided by cardiovascular risk and applicable recommendations. Rheumatic disease alone does not justify universal statin or aspirin prescribing. Drug selection must account for individual safety profiles, as comparative trial evidence does not support assuming that all anti-inflammatory therapies confer cardiovascular protection. Antithrombotic management in antiphospholipid syndrome depends on antibody profile, previous events, and bleeding risk. Uncertainty concerns optimal risk prediction, the clinical significance of subclinical abnormalities, and the cardiovascular effects of specific immunomodulators. Effective care integrates rheumatology, cardiology, pulmonary vascular expertise, and primary prevention without replacing established cardiovascular treatment with inflammation control alone. Responsibility for follow-up is necessary to translate risk recognition into individualized management across changing disease states.